Case Report : A Severe Paediatric Presentation of COVID-19 in APDS2 Immunodeficiency
Copyright © 2022 Sanchez Clemente, Penner, Breuer, Ip and Booth..
Critical respiratory manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are rare in children, and little is known about how immunocompromised children respond to the infection. We report a case of a 4-year-old boy with activated PI3K delta syndrome type 2 (APDS2) with a protracted and severe COVID-19 course with both inflammatory and acute respiratory features. He was treated with remdesivir, nitazoxanide, high-dose corticosteroids, and tocilizumab and made a full recovery. We propose that remdesivir may be used in combination with nitazoxanide to improve viral clearance and reduce the chance of resistance in treating acute SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 17., Seite 881259 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanchez Clemente, Nuria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
APDS2 |
|---|
| Anmerkungen: |
Date Completed 17.06.2022 Date Revised 16.07.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.881259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342289195 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342289195 | ||
| 003 | DE-627 | ||
| 005 | 20231226204839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.881259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342289195 | ||
| 035 | |a (NLM)35707532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanchez Clemente, Nuria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case Report |b A Severe Paediatric Presentation of COVID-19 in APDS2 Immunodeficiency |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sanchez Clemente, Penner, Breuer, Ip and Booth. | ||
| 520 | |a Critical respiratory manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are rare in children, and little is known about how immunocompromised children respond to the infection. We report a case of a 4-year-old boy with activated PI3K delta syndrome type 2 (APDS2) with a protracted and severe COVID-19 course with both inflammatory and acute respiratory features. He was treated with remdesivir, nitazoxanide, high-dose corticosteroids, and tocilizumab and made a full recovery. We propose that remdesivir may be used in combination with nitazoxanide to improve viral clearance and reduce the chance of resistance in treating acute SARS-CoV-2 infection | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a APDS2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a primary immunodeficiency | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Penner, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Breuer, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Ip, Winnie |e verfasserin |4 aut | |
| 700 | 1 | |a Booth, Claire |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 17., Seite 881259 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:17 |g pages:881259 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.881259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 17 |h 881259 | ||